• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Rare Diseases

    Roche’s Enspryng cuts relapse risk by 68% in Neuroinflammatory

    PRESS RELEASE

    Genentech Drug Fails Rare Disease Trial, Raises Obesity Risk

    FIERCE BIOTECH

    Another Setback For Enspryng As Roche Halts Duchenne Development

    FIERCE PHARMA

    Biogen Bets HD Spinraza Can Outmuscle Roche`s Oral Rival

    FIERCE PHARMA

    Sobi Tops Roche in Rare Disease Patients` Reputation Rankings

    FIERCE PHARMA

    Roche Halts Elevidys Shipments in Select Non-US Countries

    BIOSPACE

    Roche discontinues low dose in Huntington’s trial

    ENDPTS

    Oak Hill Bio Licenses Angelman Syndrome Treatment to Roche

    BUSINESSWIRE

    FDA approves Roche’s Evrysdi tablet as first & only tablet for SMA

    GLOBENEWSWIRE

    Roche Regains Reputation Crown Among Rare Disease Patient Groups

    FIERCE PHARMA

    CHMP Recommends EU Approval Of Roche’s PiaSky For PNH Blood Condition

    GLOBENEWSWIRE

    Horizon, Roche top list for pharma reputation among rare disease patient groups

    ENDPTS

    Roche May Have A Competing Drug For A Rare Disease

    SEEKING ALPHA

    Emmetuxumab injection for rare disease treatment was approved for marketing

    CHINA NMPA

    Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use

    ENDPTS

    Roche puts down $75M to sign on AMD drug, following Huntington’s deal

    ENDPTS

    FDA Approves Actemra for SJIA - Rare Form of Juvenile Arthritis

    BUSINESSWIRE

    Bayer`s hemophilia A treatment gets U.S. FDA approval

    REUTERS

    AbbVie, J&J score early nod for Imbruvica in rare cancer

    FIERCE PHARMA

    In 3 firsts, Dompe`s eye drop Oxervate wins FDA nod for rare disease

    PMLIVE

    IONIS-HTT Rx (RG6042) Granted PRIME Designation by the EMA

    PR NEWSWIRE

    Azafaros to develop new treatments for rare metabolic disorders

    BIOSPECTRUM

    Abeona taps ex-Alexion CCO as new chief, eyeing commercial ops

    FIERCE BIOTECH

    Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul

    BLOOMBERG

    Biogen, Roche ink deals with Bristol for rare disease drugs

    BIOPHARMADIVE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.